Austedo - (6, 9, 12 mg; Tablet, Oral)

Generic Name	Deutetrabenazine	Innovator	Teva
Dosage	6, 9, 12 mg; Tablet, Oral	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	Less Than 5
Final Approvals	None	Generic Launches	None
Indication	AUSTEDO is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of chorea associated with Huntington’s disease.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*********	***\ *********	*** **, ****	******	********* ********	**** ***** ****
*****	***\ *********	*** **, ****	*******	****	**** ***** ****

Chronology Of Events